HERON THERAPEUTICS, INC. /DE/ (HRTX) Financials
Annual revenue, profitability and per-share results for HERON THERAPEUTICS, INC. /DE/, as reported in SEC filings.
Revenue • FY2025
$154.9M
▲ 7.4%YoY
Net income • FY2025
-$20.2M
▼ 48.7%YoY
Gross margin • FY2025
73.3%
Diluted EPS • FY2025
-$0.12
▼ 33.3%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $154.9M | -$20.2M | $113.56M | -$0.12 | -$27.91M | -1.6% | +7.4% |
| FY2024 | $144.28M | -$13.58M | $105.64M | -$0.09 | -$24.23M | -8.0% | +13.6% |
| FY2023 | $127.04M | -$110.56M | $61.94M | -$0.80 | -$60.33M | -87.1% | +18.0% |
| FY2022 | $107.67M | -$182.02M | $52.8M | -$1.67 | -$148.74M | -162.2% | +24.7% |
Figures as reported in HERON THERAPEUTICS, INC. /DE/'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a HRTX filing.
Get an email when HRTX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.